Abstract
Autonomous parvoviruses are small, non-enveloped, lytic DNA viruses replicating in the nucleus of actively dividing mammalian cells of appropriate species and tissue origins. In contrast to AAV, the other main subgroup of parvoviruses, autonomous parvoviruses do not require the assistance of an auxiliary virus for productive infection and do not stably integrate in the cellular DNA. Therefore, autonomous parvoviruses are suitable vectors for mediating transient gene transduction in dividing target cells. Interestingly, some of these viruses possess a striking inherent oncotropism, which may render them particularly suitable as selective vehicles in the clinical context of cancer gene therapy. In this chapter, we will present a brief overview of the biology of autonomous parvoviruses. This topic will be followed by a description of the design and recent developments in the production and use of parvoviral vectors, with a particular emphasis on biosafety aspects. Finally, the risk assessment related to the production and use of parvoviral vectors will be discussed in last part of the chapter.
Keywords: Autonomous Parvovirus-Based Vectors, mammalian cells, DNA viruses, cancer gene therapy, oncotropism
Current Gene Therapy
Title: Risk Assessment of the Use of Autonomous Parvovirus-Based Vectors
Volume: 3 Issue: 6
Author(s): Francis Dupont
Affiliation:
Keywords: Autonomous Parvovirus-Based Vectors, mammalian cells, DNA viruses, cancer gene therapy, oncotropism
Abstract: Autonomous parvoviruses are small, non-enveloped, lytic DNA viruses replicating in the nucleus of actively dividing mammalian cells of appropriate species and tissue origins. In contrast to AAV, the other main subgroup of parvoviruses, autonomous parvoviruses do not require the assistance of an auxiliary virus for productive infection and do not stably integrate in the cellular DNA. Therefore, autonomous parvoviruses are suitable vectors for mediating transient gene transduction in dividing target cells. Interestingly, some of these viruses possess a striking inherent oncotropism, which may render them particularly suitable as selective vehicles in the clinical context of cancer gene therapy. In this chapter, we will present a brief overview of the biology of autonomous parvoviruses. This topic will be followed by a description of the design and recent developments in the production and use of parvoviral vectors, with a particular emphasis on biosafety aspects. Finally, the risk assessment related to the production and use of parvoviral vectors will be discussed in last part of the chapter.
Export Options
About this article
Cite this article as:
Dupont Francis, Risk Assessment of the Use of Autonomous Parvovirus-Based Vectors, Current Gene Therapy 2003; 3 (6) . https://dx.doi.org/10.2174/1566523034578104
DOI https://dx.doi.org/10.2174/1566523034578104 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Magnetic Nanoparticles: New Players in Antimicrobial Peptide Therapeutics.
Current Protein & Peptide Science Theranostic Radiopharmaceuticals Targeting Cancer-Associated Fibroblasts
Current Radiopharmaceuticals The Glycogen Synthase Kinase-3 in the Regulation of Ion Channels and Cellular Carriers
Current Medicinal Chemistry Cellular and Biochemical Alterations Caused by Artificial Depletion of Glutathione
Current Enzyme Inhibition Curcumin and its Formulations: Potential Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Advanced Neuroimaging Techniques in the Management of Glioblastoma Multiforme
Current Radiopharmaceuticals The Pros and Cons of Targeting Protein Kinase c (PKC) in the Management of Cancer Patients
Current Pharmaceutical Biotechnology Approaches Targeting KV10.1 Open a Novel Window for Cancer Diagnosis and Therapy
Current Medicinal Chemistry Autoimmunity and Frontotemporal Dementia
Current Alzheimer Research Resistance to Anti-VEGF Agents
Current Pharmaceutical Design Benzamides as Melanotropic Carriers for Radioisotopes, Metals, Cytotoxic Agents and as Enzyme Inhibitors
Current Medicinal Chemistry In Vitro Models of the Blood-Brain Barrier: When to Use Which?
Current Medicinal Chemistry - Central Nervous System Agents CXCR4 and Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry EGFR Intron Recombination in Human Gliomas: Inappropriate Diversion of V(D)J Recombination?
Current Genomics Perspectives/Opinion: ADVANCED MEDICAL IMAGING IN THE ERA OF PERSONALIZED OR PRECISION MEDICINE
Current Medical Imaging The MCM Complex: Its Role in DNA Replication and Implications for Cancer Therapy
Current Cancer Drug Targets Neurodegenerative Diseases of the Retina and Potential for Protection and Recovery
Current Neuropharmacology Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Current Drug Targets Ceramide in Chemotherapy of Tumors
Recent Patents on Anti-Cancer Drug Discovery An Overview of Nanoformulated Nutraceuticals and their Therapeutic Approaches
Current Nutrition & Food Science